MedPath

Evaluation of the Donepezil and Rivastigmine co – administration on the cognitive deficits induced by EcT: A Randomized Double Blind Clinical Trial

Phase 3
Conditions
EcT in patients with Mood Disorders.
Bipolar affective disorder
Registration Number
IRCT20171229038124N1
Lead Sponsor
Ahvaz University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
60
Inclusion Criteria

Schizophrenia Disorder
Schizoaffective Disorder
Bipolar Mood Disorder
Major Depressive Disorder
ECT 6-12 Sessions

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Evaluation of cognitive function by MMSE. Timepoint: In the first, middle and end of the period of ECT Therapy. Method of measurement: MMSE.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath